Hereditary Cancer Testing (HCT) panel

Gene name / Alternate gene name

See requisition for gene list(s)

Lab area

Genome Diagnostics - Molecular Genetics

Method and equipment

Sequencing (all genes) by Next Generation Sequencing.

Expected turn-around time

STAT: 4 weeks Routine: 6 weeks

Specimen type

Blood; please contact the Genome Diagnostics Laboratory if you want to send gDNA.

For details about specimen requirements, please refer to: Specimen Types & Requirements.

Specimen requirements

Blood: 5-10 mL in EDTA, 0.5 mL in EDTA (neonate);

DNA-minimum 10 ug in 100 uL low TE (pH8.0)

Storage and transportation

Blood- Room Temperature. Please contact the Genome Diagnostics Laboratory if you want to send gDNA.

If sample shipment >48 hours, ship on ice.

Special requirements

Special Instructions for Genome Diagnostics Samples

Please ship us the blood sample within 48 hours of collection.

Shipping information

The Hospital for Sick Children

Division of Genome Diagnostics

555 University Avenue, Black Wing, Room 3416

Toronto, ON

Canada

M5G 1X8

Phone: 416-813-7200 ext. 2

Hours: Monday to Friday, 8 a.m. to 4:30 p.m.

Background and clinical significance

Cancer genetic counselling and assessment is a process that utilizes clinical assessment and genetic testing, when indicated, to provide cancer risk management recommendations to individuals with a personal and/or family history of cancer. Cancer genetic testing is often an integral component of surgical, radiation, and systemic treatment planning for oncology patients. Advances in technology, including next generation sequencing, have facilitated rapid high-throughput analysis of cancer multi-gene panels in both somatic and germline samples making genetic testing faster, less expensive, and more accessible to a greater number of individuals. Implementation of the Provincial Hereditary Cancer Testing Program and associated eligibility criteria has increased clinically appropriate access to cancer genetic testing.

Disease condition

Comprehensive Panel, Hereditary Cancer Core Panel, Hereditary Breast / Ovarian / Prostate, Hereditary GI (Lynch, Colorectal, Endometrial, Gastric, Pancreas, Polyposis), Gastric Cancer, Polyposis, Pancreatic Cancer, GIST, Sarcoma, Hereditary Pheochromocytoma and Paraganglioma (PPGL), CNS, Hereditary Melanoma, Hereditary Renal, Lung Cancer, Medulloblastoma, Nephroblastoma (Wilms tumour), Neuroblastoma, AXIN2-related Attenuated Familial Adenomatous Polyposis, BAP1 Tumour Predisposition Syndrome, Birt-Hogg-Dube Syndrome, Carney Complex, DICER-associated Syndrome, Dysplastic Nevus Syndrome, Familial Adenomatous Polyposis (CHRPE, CMV Thyroid, Desmoid), Familial Adenomatous Polyposis (CHRPE, CMV Thyroid, Desmoid) Plus MUTYH, Familial Isolated Pituitary Adenoma, Hereditary Parathyroid Neoplasia, Hereditary Leiomyomatosis and Renal Cell Cancer, Hereditary Multiple Osteochondromas, Li-Fraumeni Syndrome, MBD4 Tumour Predisposition Syndrome, Multiple Endocrine Neoplasia, Type 1, Multiple Endocrine Neoplasia, Type 2, Neurofibromatosis, Type 1, Nevoid Basal Cell Carcinoma Syndrome / Gorlin Syndrome, Nijmegen Breakage Syndrome, Peutz-Jeghers Syndrome, PTEN Hamartoma Tumour Syndrome, Rare Polyposis Genes, Retinoblastoma, Rhabdoid Predisposition Syndrome, Schwannomatosis, Sessile Serrated Polyposis Cancer Syndrome, Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT), Tuberous Sclerosis, Von Hippel-Lindau Syndrome, Ashkenazi Jewish Panel